Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-377-6 | CAS number: 81-81-2
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
Data source
Referenceopen allclose all
- Reference Type:
- review article or handbook
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
- Reference Type:
- secondary source
- Title:
- The warfarin embryopathy: a rat model showing maxillonasal hypoplasia other skeletal disturbances
- Author:
- Howe AM, Webster WS
- Year:
- 1 992
- Bibliographic source:
- Teratology 46, 379-390
- Reference Type:
- secondary source
- Title:
- Effect of sodium warfarin on vitamin K-dependent proteins and skeletal development in the rat fetus
- Author:
- Feteih R, Tassinari MS, Lian JB
- Year:
- 1 990
- Bibliographic source:
- J. Bone Miner. Res. 5, 885-894
- Reference Type:
- secondary source
- Title:
- Experimental evaluation of the risk of prenatal pathology with the application of the coumarine rodenticide warfarin
- Author:
- Mirkova E, Antov G
- Year:
- 1 983
- Bibliographic source:
- Hig. Zdrav. 25, 476-482
Materials and methods
- Principles of method if other than guideline:
- Method data are not available.
- GLP compliance:
- no
Test material
- Reference substance name:
- Warfarin
- EC Number:
- 201-377-6
- EC Name:
- Warfarin
- Cas Number:
- 81-81-2
- Molecular formula:
- C19H16O4
- IUPAC Name:
- 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
Constituent 1
Test animals
- Species:
- rat
Administration / exposure
- Route of administration:
- subcutaneous
Results and discussion
Results: maternal animals
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 0.04 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
- Effect level:
- >= 0.04 - <= 8 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
- Effect level:
- 100 mg/kg bw/day
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
Haemorrhagic syndrome in foetuses, structural malformations of the hind limbs, internal hydrocephalus, metabolic damage of foetus livers (rat, repeated dose of 0.04 - 8 mg/kg bw/day); maxillonasal hypoplasia, calcium deposits in cartilage of the nasal septum and epiphyseal cartilage of vertebrae and long bones (rat, 100 mg/kg bw subcutaneous injection)
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
